Konakion Mm Ampoules (Phytomenadione)

Phytomenadione serves as a co‑factor for the enzyme gamma‑glutamyl carboxylase, enabling the gamma‑carboxylation of specific glutamate residues on clotting factors II, VII, IX and X. This modification converts the factors into their active forms, thereby re‑establishing the normal coagulation cascade and reducing bleeding risk.

The exact dose of Konakion Mm Ampoules is determined by the prescribing clinician based on the patient’s age, weight, clinical condition and the severity of vitamin K deficiency. Healthcare professionals calculate the appropriate amount and administration rate according to established guidelines and individual patient needs.

Safety data for phytomenadione during pregnancy and lactation are limited. It should only be used when clearly indicated and after a careful risk‑benefit assessment by a qualified healthcare provider. The prescriber will decide if the benefits to the mother or infant outweigh any potential risks.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Konakion Mm Ampoules. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Konakion Mm contains phytomenadione, a natural form of vitamin K1, similar to other injectable preparations such as Kogenate or Mephyton. Compared with synthetic analogues, phytomenadione has a well‑established safety profile and rapid onset of action. Choice of product often depends on local availability, regulatory approval and specific clinical protocols.

Konakion Mm Ampoules must be stored refrigerated at 2‑8 °C, protected from light, and must never be frozen or shaken. Before use, inspect the ampoule for any particulate matter or discoloration. Keep the product in its original packaging until administration to maintain stability.

The ampoule is intended for intravenous use. It should be administered slowly, typically as an infusion over several minutes, to minimize the risk of hypotension or other infusion‑related reactions. Administration techniques follow standard aseptic procedures and the prescribing clinician’s instructions.

Serious adverse reactions, although rare, include anaphylaxis, severe allergic responses, and thrombotic events such as unexpected clot formation. Immediate medical attention is required if signs of a severe reaction appear, such as difficulty breathing, rash, swelling, or sudden chest pain.

Konakion Mm Ampoules should be avoided in individuals with known hypersensitivity to phytomenadione or any of the excipients in the formulation. Caution is also advised for patients with severe liver disease, uncontrolled hypertension, or those who have experienced previous severe allergic reactions to vitamin K preparations.